Browsing by Author "Jefferson, Michelle A."

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Evaluating Thera-101 as a Low-Volume Resuscitation Fluid in a Model of Polytrauma
    (MDPI, 2022-10-21) Shah, Jessica Stukel; Macaitis, Joseph; Lundquist, Bridney; Johnstone, Brian; Coleman, Michael; Jefferson, Michelle A.; Glaser, Jacob; Rodriguez, Annette R.; Cardin, Sylvain; Wang, Heuy-Ching; Burdette, Alexander; Emergency Medicine, School of Medicine
    Traumatic brain injury (TBI) and hemorrhage remain challenging to treat in austere conditions. Developing a therapeutic to mitigate the associated pathophysiology is critical to meet this treatment gap, especially as these injuries and associated high mortality are possibly preventable. Here, Thera-101 (T-101) was evaluated as low-volume resuscitative fluid in a rat model of TBI and hemorrhage. The therapeutic, T-101, is uniquely situated as a TBI and hemorrhage intervention. It contains a cocktail of proteins and microvesicles from the secretome of adipose-derived mesenchymal stromal cells that can act on repair and regenerative mechanisms associated with poly-trauma. T-101 efficacy was determined at 4, 24, 48, and 72 h post-injury by evaluating blood chemistry, inflammatory chemo/cytokines, histology, and diffusion tensor imaging. Blood chemistry indicated that T-101 reduced the markers of liver damage to Sham levels while the levels remained elevated with the control (saline) resuscitative fluid. Histology supports the potential protective effects of T-101 on the kidneys. Diffusion tensor imaging showed that the injury caused the most damage to the corpus callosum and the fimbria. Immunohistochemistry suggests that T-101 may mitigate astrocyte activation at 72 h. Together, these data suggest that T-101 may serve as a potential field deployable low-volume resuscitation therapeutic.